

Nicola Fusco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6750887/publications.pdf>

Version: 2024-02-01

140
papers

2,870
citations

186209

28
h-index

243529

44
g-index

143
all docs

143
docs citations

143
times ranked

3089
citing authors

#	ARTICLE	IF	CITATIONS
1	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. <i>Nature Genetics</i> , 2014, 46, 1166-1169.	9.4	188
2	The Genomic Landscape of Male Breast Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 4045-4056.	3.2	119
3	<i>MED12</i> somatic mutations in fibroadenomas and phyllodes tumours of the breast. <i>Histopathology</i> , 2015, 67, 719-729.	1.6	78
4	<i>MYBL1</i> rearrangements and <i>MYB</i> amplification in breast adenoid cystic carcinomas lacking the <i>MYB</i> – <i>NFIB</i> fusion gene. <i>Journal of Pathology</i> , 2018, 244, 143-150.	2.1	74
5	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky056.	1.4	71
6	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737.	1.3	70
7	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. <i>Modern Pathology</i> , 2016, 29, 1292-1305.	2.9	68
8	Expression and Clinical Significance of the Autophagy Proteins BECLIN 1 and LC3 in Ovarian Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	67
9	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719.	1.0	67
10	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	1.6	63
11	HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. <i>Modern Pathology</i> , 2013, 26, 816-824.	2.9	57
12	Tackling the diversity of breast cancer related lymphedema: Perspectives on diagnosis, risk assessment, and clinical management. <i>Breast</i> , 2019, 44, 15-23.	0.9	54
13	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. <i>Journal of Pathology</i> , 2015, 237, 166-178.	2.1	53
14	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
15	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring <i>TP53</i> somatic mutations. <i>Journal of Pathology</i> , 2016, 238, 677-688.	2.1	52
16	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 556718.	1.3	49
17	The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. <i>Diagnostics</i> , 2021, 11, 339.	1.3	46
18	<i>HER2</i> aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists. <i>World Journal of Gastroenterology</i> , 2016, 22, 7926.	1.4	43

#	ARTICLE	IF	CITATIONS
19	Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 959-962.	1.4	39
20	Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy. <i>Molecular Therapy</i> , 2016, 24, 1898-1912.	3.7	37
21	Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging. <i>Journal of Proteomics</i> , 2019, 191, 114-123.	1.2	37
22	Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. <i>Cancers</i> , 2020, 12, 1598.	1.7	37
23	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. <i>Oncotarget</i> , 2018, 9, 20617-20630.	0.8	36
24	Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. <i>Lung Cancer</i> , 2020, 150, 53-61.	0.9	36
25	PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols. <i>Cancers</i> , 2021, 13, 292.	1.7	36
26	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. <i>Journal of Personalized Medicine</i> , 2022, 12, 1073.	1.1	36
27	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. <i>Cells</i> , 2021, 10, 1377.	1.8	35
28	Editorial: Quality of Life in Breast Cancer Patients and Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 620574.	1.3	33
29	Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. <i>BMC Cancer</i> , 2018, 18, 935.	1.1	32
30	Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability. <i>Thyroid</i> , 2019, 29, 237-251.	2.4	31
31	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 593-605.	1.9	31
32	Recurrent <i>NAB2</i> and <i>STAT6</i> gene fusions and oestrogen receptor expression in pulmonary adenofibromas. <i>Histopathology</i> , 2017, 70, 906-917.	1.6	29
33	The Genetic Landscape of Human Glioblastoma and Matched Primary Cancer Stem Cells Reveals Intratumour Similarity and Intertumour Heterogeneity. <i>Stem Cells International</i> , 2019, 2019, 1-12.	1.2	29
34	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. <i>Advances in Anatomic Pathology</i> , 2019, 26, 270-279.	2.4	29
35	Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	29
36	Axillary web syndrome in women after breast cancer surgery referred to an Oncological Rehabilitation Unit: which are the main risk factors? A retrospective case-control study. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 8028-8035.	0.5	29

#	ARTICLE	IF	CITATIONS
37	Breast Cancer Systemic Treatments and Upper Limb Lymphedema: A Risk-Assessment Platform Encompassing Tumor-Specific Pathological Features Reveals the Potential Role of Trastuzumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 138.	1.0	28
38	Three-dimensional laser scanning as a reliable and reproducible diagnostic tool in breast cancer related lymphedema rehabilitation: a proof-of-principle study. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 4476-4485.	0.5	28
39	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1750-1761.	0.5	27
40	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. <i>Cancer Treatment Reviews</i> , 2020, 90, 102089.	3.4	27
41	<p>Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 675-686.	0.9	27
42	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. <i>Ecancermedicalscience</i> , 2020, 14, 1150.	0.6	27
43	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. <i>Cancer Cell International</i> , 2021, 21, 266.	1.8	26
44	Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 510.	1.8	25
45	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1461.	1.8	25
46	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800.	0.9	25
47	Impact of exercise training on muscle mitochondria modifications in older adults: a systematic review of randomized controlled trials. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1495-1510.	1.4	25
48	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103643.	2.0	25
49	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. <i>Translational Cancer Research</i> , 2020, 9, 4060-4064.	0.4	24
50	Lack of <i><sc>PRKD</sc>2</i> and <i><sc>PRKD</sc>3</i> kinase domain somatic mutations in <i><sc>PRKD</sc>1</i> wild-type classic polymorphous low-grade adenocarcinomas of the salivary gland. <i>Histopathology</i> , 2016, 68, 1055-1062.	1.6	23
51	Spinal Cord Injury as a Model of Bone-Muscle Interactions: Therapeutic Implications From in vitro and in vivo Studies. <i>Frontiers in Endocrinology</i> , 2020, 11, 204.	1.5	23
52	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	1.6	22
53	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma". <i>Journal of Pathology Informatics</i> , 2021, 12, 1.	0.8	22
54	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	2.1	21

#	ARTICLE	IF	CITATIONS
55	Effects of hypnosis on the relative parasympathetic tone assessed by ANI (Analgesia/Nociception Index) in healthy volunteers: a prospective observational study. <i>Journal of Clinical Monitoring and Computing</i> , 2018, 32, 487-492.	0.7	20
56	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	20
57	Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients' Quality of Life. <i>Current Osteoporosis Reports</i> , 2020, 18, 422-431.	1.5	20
58	Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: Synergy among nutritional supplementation, pharmacotherapy, and rehabilitation. <i>Current Opinion in Pharmacology</i> , 2021, 57, 132-139.	1.7	20
59	Circulating and tissue biomarkers in early-stage non-small. <i>Ecancermedicalscience</i> , 2017, 11, 717.	0.6	19
60	Quality of Life Interventions in Breast Cancer Survivors: State of the Art in Targeted Rehabilitation Strategies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 801-810.	0.9	19
61	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 829875.	1.3	19
62	Pathology after neoadjuvant treatment – How to assess residual disease. <i>Breast</i> , 2022, 62, S25-S28.	0.9	18
63	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. <i>Frontiers in Oncology</i> , 2020, 10, 422.	1.3	17
64	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	1.3	16
65	Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor-Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1369.	1.1	14
66	Gluten Induces Subtle Histological Changes in Duodenal Mucosa of Patients with Non-Coeliac Gluten Sensitivity: A Multicentre Study. <i>Nutrients</i> , 2022, 14, 2487.	1.7	14
67	Juxtaglomerular Cell Tumor: Multicentric Synchronous Disease Associated With Paraneoplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2013, 31, e240-e242.	0.8	13
68	Lymphedema Rehabilitation Using Self-Adaptive Inelastic Compression in Breast Cancer: A Proof-of-Principle Study. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 1901.	1.3	13
69	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022, 12, 750.	1.1	13
70	The Contrasting Role of p16Ink4A Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations. <i>PLoS ONE</i> , 2015, 10, e0144923.	1.1	12
71	Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3014.	1.8	12
72	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. <i>Cancers</i> , 2020, 12, 1800.	1.7	12

#	ARTICLE	IF	CITATIONS
73	Vitamin D Deficiency in Women with Breast Cancer: A Correlation with Osteoporosis? A Machine Learning Approach with Multiple Factor Analysis. <i>Nutrients</i> , 2022, 14, 1586.	1.7	12
74	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	11
75	Columnar Cell Lesion and Apocrine Hyperplasia of the Breast: Is There a Common Origin? The Role of Prolactin-induced Protein. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 508-514.	0.6	11
76	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. <i>Histology and Histopathology</i> , 2021, , 18376.	0.5	11
77	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. <i>Journal of Molecular Pathology</i> , 2021, 2, 93-100.	0.5	10
78	The Birth of an Adenoid Cystic Carcinoma. <i>International Journal of Surgical Pathology</i> , 2015, 23, 26-27.	0.4	9
79	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. <i>BMC Cancer</i> , 2021, 21, 1152.	1.1	9
80	Clonal reticulohistiocytosis of the skin and bone marrow associated with systemic mastocytosis and acute myeloid leukaemia. <i>Histopathology</i> , 2017, 70, 1000-1008.	1.6	8
81	Cofilin is a cAMP effector in mediating actin cytoskeleton reorganization and steroidogenesis in mouse and human adrenocortical tumor cells. <i>Cancer Letters</i> , 2017, 406, 54-63.	3.2	8
82	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021, 10, 1412.	1.0	8
83	Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients. <i>Current Opinion in Pharmacology</i> , 2021, 58, 27-34.	1.7	8
84	An EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls. <i>Frontiers in Oncology</i> , 2021, 11, 643280.	1.3	8
85	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. <i>Frontiers in Oncology</i> , 2021, 11, 723693.	1.3	8
86	Axillary Web Syndrome in Breast Cancer Women: What Is the Optimal Rehabilitation Strategy after Surgery? A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 3839.	1.0	8
87	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. <i>Advances in Anatomic Pathology</i> , 2016, 23, 170-179.	2.4	7
88	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. <i>Gastrointestinal Disorders</i> , 2020, 2, 341-352.	0.4	7
89	RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 265-266.	1.1	7
90	Comparing prognostic utility between the 8th edition of <scp>TNM</scp> staging system and the lymph node ratio for oral squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 2876-2882.	0.9	7

#	ARTICLE	IF	CITATIONS
91	Metaplastic breast cancers and triple-negative breast cancers of no special type. <i>European Journal of Cancer Prevention</i> , 2021, Publish Ahead of Print, .	0.6	7
92	Autoimmune Hepatitis: An Uncommon Presentation of Thymoma. <i>Tumori</i> , 2016, 102, S40-S42.	0.6	6
93	TdT expression in germ cell tumours: a possible immunohistochemical cross-reaction and diagnostic pitfall. <i>Journal of Clinical Pathology</i> , 2019, 72, 536-541.	1.0	6
94	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. <i>Current Drug Targets</i> , 2021, 22, 1021-1033.	1.0	6
95	Role of multidisciplinary approach in a case of Langerhans cell histiocytosis with initial periodontal manifestations. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13539-45.	0.5	6
96	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. <i>Cancers</i> , 2022, 14, 370.	1.7	6
97	Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC). <i>Pathologica</i> , 2022, 114, 104-110.	1.3	6
98	High Expression of Cathepsin D in Non-Hodgkin's Lymphomas Negatively Impacts on Clinical Outcome. <i>Disease Markers</i> , 2010, 28, 167-183.	0.6	5
99	A novel integrated platform for the identification of surgical margins in oral squamous cell carcinoma: results from a prospective single-institution series. <i>BMC Cancer</i> , 2019, 19, 467.	1.1	4
100	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. <i>Future Oncology</i> , 2021, 17, 4607-4618.	1.1	4
101	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. <i>BJU International</i> , 2022, 129, 524-533.	1.3	4
102	"Giants in a Microcosm". <i>International Journal of Surgical Pathology</i> , 2015, 23, 654-655.	0.4	3
103	Looking for sputum biomarkers in lung cancer secondary prevention: where are we now?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4277-4279.	0.6	3
104	<i>NF1</i> Alterations are Linked to Increased HER2 Expression in Breast Cancer"Letter. <i>Cancer Prevention Research</i> , 2019, 12, 195-196.	0.7	3
105	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	0.9	3
106	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	1.2	3
107	High expression of cathepsin D in non-Hodgkin's lymphomas negatively impacts on clinical outcome. <i>Disease Markers</i> , 2010, 28, 167-83.	0.6	3
108	Lights on HBME-1: the elusive biomarker in thyroid cancer pathology. <i>Journal of Clinical Pathology</i> , 2022, 75, 588-592.	1.0	3

#	ARTICLE	IF	CITATIONS
109	Basal Cell Carcinoma and Seborrheic Keratosis. International Journal of Surgical Pathology, 2015, 23, 464-464.	0.4	2
110	Hibernation in Unusual Places: A Pure Typical Hibernoma of the Breast. Breast Journal, 2017, 23, 104-105.	0.4	2
111	Premalignant and Pre-invasive Lesions of the Breast. , 2017, , 103-120.		2
112	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids- a short report. Cellular Oncology (Dordrecht), 2018, 41, 687-691.	2.1	2
113	The conundrum of breast chondrolipoma: Heterotopic, metaplastic, or neoplastic lesion?. Breast Journal, 2019, 25, 733-734.	0.4	2
114	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Frontiers in Oncology, 2021, 11, 735476.	1.3	2
115	Approaching the histodynamics of celiac disease in modern times: the need of going beyond the dogmas. Digestive and Liver Disease, 2016, 48, 449-450.	0.4	1
116	Chondroid Differentiation in Thyroid Nodular Hyperplasia: An Innocent Bystander?. International Journal of Surgical Pathology, 2019, 27, 274-274.	0.4	1
117	Diagnostic challenge of intrathoracic tissue misplacements: a thymic choristoma in a fetal lung. Thorax, 2019, 74, 624-624.	2.7	1
118	Abstract S6-06: The genomic landscape of male breast cancers. , 2015, , .		1
119	29P The molecular landscape of breast mucoepidermoid carcinoma. Annals of Oncology, 2022, 33, S136-S137.	0.6	1
120	CT-guided fine-needle aspiration biopsy of pulmonary lesions under 15 mm of diameter: results on 68 consecutive patients. Annals of Oncology, 2016, 27, iv12.	0.6	0
121	Rathke's cleft cyst associated with pituitary granulomatosis with polyangiitis: An unusual combination of hypothalamus-pituitary region pathologies. Radiology Case Reports, 2018, 13, 233-236.	0.2	0
122	PWE-035-Global translation of coeliac disease histology and other gluten related microenteropathy. , 2019, , .		0
123	Abstract PS9-36: Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study. , 2021, , .		0
124	10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers. Annals of Oncology, 2021, 32, S25.	0.6	0
125	Abstract P5-06-07: PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer. , 2017, , .		0
126	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2018, , 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
127	Lymphovascular invasion and extranodal tumor extension as risk indicators of breast cancer-related lymphedema.. Journal of Clinical Oncology, 2018, 36, e12609-e12609.	0.8	0
128	Abstract P1-12-09: Proposal for integrating the pathologic assessment of lymphovascular invasion and extranodal tumor extension in breast cancer-related lymphedema clinical management. , 2019, , .		0
129	Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related. , 2019, , .		0
130	Abstract P2-08-21: Mismatch repair protein loss is a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. , 2019, , .		0
131	Tubular Adenoma of the Breast. Encyclopedia of Pathology, 2020, , 379-384.	0.0	0
132	Abstract P2-05-03: Integrated analysis of mismatch repair, PD-L1, and immune microenvironment status in pregnancy-associated breast cancers. , 2020, , .		0
133	Abstract P4-07-02: Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes. Cancer Research, 2022, 82, P4-07-02-P4-07-02.	0.4	0
134	Abstract P4-07-01: Loss of HER2 on residual disease after neoadjuvant therapy in HER2-positive early breast cancer: Clinicopathological characteristics and association with outcomes. Cancer Research, 2022, 82, P4-07-01-P4-07-01.	0.4	0
135	Abstract P3-18-08: Feasibility and safety of breast-conserving surgery in early-stage breast cancers during the first trimester of pregnancy. Cancer Research, 2022, 82, P3-18-08-P3-18-08.	0.4	0
136	Abstract P4-10-15: Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study. Cancer Research, 2022, 82, P4-10-15-P4-10-15.	0.4	0
137	Abstract P4-10-23: Combined analysis of PTEN and routinely assessed biomarkers reveals new high-risk subgroups of HR- or HER2+ breast cancers. Cancer Research, 2022, 82, P4-10-23-P4-10-23.	0.4	0
138	Abstract P1-22-03: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ. Cancer Research, 2022, 82, P1-22-03-P1-22-03.	0.4	0
139	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	1.2	0
140	Hereditary gastric and breast cancer syndromes with lung metastasis: narrative review of molecular and clinical insights. AME Surgical Journal, 0, .	0.0	0